Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Gastrointestinal Neoplasms: early-phase trial registry
7 of 13 indexed Gastrointestinal Neoplasms trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,315 of 28,707 conditions by registered trial count.
13 US clinical trials · 7 currently recruiting · #1,315 of 28,707 conditions by registered trial count
Gastrointestinal Neoplasms: 13 US clinical trials tracked, 7 recruiting.
Gastrointestinal Neoplasms is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is GlaxoSmithKline, running 2 of these trials.
Enrollment posture brief
Registry condition gastrointestinal-neoplasms
OPEN 7 | RECR 54% | LATE 3 | EARLY 6 | RANK #1315 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Advanced Renal Cell Carcinoma (54% recruiting · 13 trials)
Gastrointestinal Neoplasms lists 7 open slots (54% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Gastrointestinal Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Gastrointestinal Neoplasms is recruiting above its size-band peers.
7 of 13 indexed trials (53.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Gastrointestinal Neoplasms research.
GlaxoSmithKline accounts for 2 of 13 trials (15.4%). 12 distinct sponsors appear on at least one study for this condition label.
-
Typical Gastrointestinal Neoplasms enrolment sits around 278 participants.
Median target enrolment is 278 among the 13 trials that report a genuine target (sentinel values excluded). 5 of those (38.5%) plan for fewer than 100 participants.
-
Gastrointestinal Neoplasms research is mostly interventional.
12 interventional and 1 observational studies make up this index (92.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
13 total, page 1 of 1
Clinical Outcomes of the Endoscopic Resection of Premalignant and Malignant Gastrointestinal Lesions
California Pacific Medical Center Research Institute
NCT01750619
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Pfizer
NCT07222800
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
GlaxoSmithKline
NCT07218926
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Cedars-Sinai Medical Center
NCT04907643
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed
GlaxoSmithKline
NCT06885034
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
IDRx Inc. - A GSK Company
NCT05489237
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
Janssen Research & Development
NCT06663319
Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer
AstraZeneca
NCT04592913
Monopolar Current Cutting Knife vs Bipolar RFA Knife
Baylor College of Medicine
NCT04919824
Avatrombopag vs. Placebo for CIT in GI Malignancies
Hanny Al-Samkari, MD
NCT05772546
Crossover Trial of Systemic Chemotherapy in Patients With Metastatic Well-Differentiated Mucinous Appendiceal Adenocarcinomas With Pseudomyxoma Peritonei
M.D. Anderson Cancer Center
NCT01946854
Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
Pharmacyclics
NCT00120939
A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib
Exelixis
NCT00570635
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 2 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Gastrointestinal Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Gastrointestinal Neoplasms trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Gastrointestinal Neoplasms page
13 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Gastrointestinal Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- GlaxoSmithKline sponsors the most Gastrointestinal Neoplasms trials on record, review their full trial history before evaluating a specific study. See GlaxoSmithKline's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Gastrointestinal Neoplasms condition card totals 13 registered trials; most-linked intervention IDRX-42; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.